Unitaid 278d ago

“Even the most promising innovation cannot reach its potential without being affordable,” said Carmen Pérez Casas, Senior strategy lead at Unitaid. “Lenacapavir is a revolutionary tool for HIV prevention, but equitable access is what will unlock its full impact.” That is why Unitaid, together with partners and generic manufacturers, has secured a $40 annual price for injectable lenacapavir, the same as oral PrEP. Generics are expected in low- and middle-income countries as early as 2027, less than two years after the first regulatory approvals in high-income countries, showing what is possible when affordability is prioritized from the start. A second US$40 pricing agreement between the Gates Foundation and Hetero Labs was announced today for injectable lenacapavir, helping to grow the market and secure sustainable and sufficient supplies of the breakthrough prevention tool. Our work now is to support countries and communities to drive adoption, remove barriers, and build sustainable markets so lenacapavir can truly reach all who need it and deliver on its promise to transform HIV prevention. Learn more: https://unitaid.org/lenacapavir